CALA Calithera Biosciences, Inc.

Partial data

NAS · US · Financial Services · Shell Companies · calithera.com

0.0003USD0.00%Mkt Cap: 1461 $P/E: —20d ago

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosc…

Industry Peers

Shell Companies

Armada Acquisition Corp. II

$790.07MUSDP/E 227.4

DMII

Drugs Made In America Acquisition II Corp.

$649.10MUSDP/E 34.0

CCXI

Churchill Capital Corp XI

$626.07MUSD

EVAC

EQV Ventures Acquisition Corp. II

$602.60MUSDP/E 34.4

BCSS

Bain Capital GSS Investment Cor

$596.85MUSD

CXII

Churchill Capital Corp XII

$591.61MUSD

CEPF

Cantor Equity Partners IV, Inc.

$586.93MUSDP/E 31.1

AC8

Intuitive Investments Group Plc

$532.06MUSDP/E 2.5

AEXA

American Exceptionalism Acquisition Corp. A

$536.65MUSD

NWAX

New America Acquisition I Corp.

$500.24MUSD

AAC

Ares Acquisition Corporation III

$496.66MUSD

MLAA

Mountain Lake Acquisition Corp. II

$490.34MUSD

KRSP

Rice Acquisition Corporation 3

$486.71MUSD

BRTM

B&R Technology Merger Corp.

$478.69MUSD

CRAN

Crane Harbor Acquisition Corp. II

$473.69MUSD

GTEN

Gores Holdings X, Inc.

$470.58MUSDP/E 21.3

GCGR

General Catalyst Global Resilience Merger Corp.

$467.87MUSD

APXT

Apex Treasury Corporation

$466.49MUSD

BCCQ

Bleichroeder Acquisition Corp. III

$457.24MUSD

Key Statistics

Company

Market Cap1.46K USD

Enterprise Value-1.44M USD

Revenue (TTM)—

Gross Profit-28.53M USD

Net Income (TTM)-39.65M USD

Revenue/Share—

Last Price0.0003 USD

Fiscal Year EndDec 2022

MR QuarterDec 2022

Employees8

CountryUS

SectorFinancial Services

IndustryShell Companies

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.00

PEG—

EV/EBITDA0.03

EV/Revenue—

P/S—

P/B-0.00

EPS (TTM)-3.97

EPS (Forward)-1.35

52W Range

0.000122% of range0.0010

52W High0.0010 USD

52W Low0.0001 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-194.44%

ROA-138.27%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-43.61M USD

CapEx (TTM)133.00K USD

FCF Margin—

FCF Yield-1928422.31%

Net Debt-23.79M USD

Net Debt/EBITDA0.57

Balance Sheet

Debt/Equity0.08

Current Ratio3.60

Quick Ratio3.44

Book Value/Sh-0.40 USD

Cash/Share5.22 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:20

Split DateJun 15, 2022

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.4.87M

Float4.83M

Insiders0.00%

Institutions0.00%

Short Interest

Short Ratio0.8d

Short % Float8.92%

Short % Out.8.57%

Shares Short417.28K

Short (prev mo.)148.51K

Technical

SMA 500.0002 (+27.1%)

SMA 2000.0002 (+23.3%)

Beta-1.28

S&P 52W Chg13.94%

Avg Vol (30d)127

Avg Vol (10d)250

Technical Indicators

RSI (14)54.9

MACD0.0000

MACD Signal0.0000

MACD Hist.+0.0000

BB Upper0.0005 USD

BB Middle0.0002 USD

BB Lower0.0000 USD

BB Width182.57%

ATR (14)0.0000 USD

Vol Ratio (20d)0.00x